NC
BEAM icon

nVerses Capital’s Beam Therapeutics BEAM Stock Holding History

nVerses Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
+6,974
New +$211K 0.37% 123

Other funds holding BEAM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $2.17B AUM 134.87% 1-Year Est. Return

nVerses Capital's BEAM Position: Q2 2026 in Review

nVerses Capital opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 6,974 shares worth $239K. The stake represents 0.37% of the portfolio and ranks #123 among its holdings.

195 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • nVerses Capital held 6,974 shares of Beam Therapeutics worth $239K as of Q2 2026.
  • Beam Therapeutics was a new nVerses Capital position in Q2 2026.
  • Beam Therapeutics made up 0.37% of nVerses Capital's portfolio in Q2 2026, its #123 holding.
  • 195 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.